TEHRAN – The preclinical article and phase one of the clinical study of the Noora vaccine were published in the international journal of Medical Virology.

Noora is the sixth Iranian-made vaccine against coronavirus that received emergency use permits from the Ministry of Health, after COVIRAN, Pastu Covac, Razi Cov Pars, Spikogen, and Fakhra, to be included in the country’s vaccination process.

Noora is a recombinant protein vaccine, and initial studies show that this vaccine can provide high immunity to the omicron strain.

Phase one clinical study article on the vaccine is entitled " Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults” by Jafar Salimian, and Jafar Amani.

In this study, it has been stated that the dose of 80 micrograms is safe as a vaccine and provides adequate immunity in adults.

The Journal of Medical Virology is a monthly peer-reviewed medical journal covering fundamental and applied research concerning viruses that affect humans. It is published by Wiley-Blackwell and was established in 1977. The current editor-in-chief is Shou-Jiang Gao.
World Health Organization representative to Iran Jaffar Hussain said in September 2021 that the Organization was collecting the necessary information for the registration and certification of Iranian-made coronavirus vaccines.

On January 28, the process for global registration of the Iranian-made “COVIRAN Barkat” vaccine started by holding a virtual meeting with the World Health Organization officials.

COVIRAN is the first vaccine in West Asia that is in the process of global registration.

FB/MG